Overview

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide + Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients with Seasonal Allergic Rhinitis exposed to controlled ragweed pollen.

Phase:

Phase 2

Details

Lead Sponsor:

Ligand Pharmaceuticals

Treatments:

Azelastine
Budesonide